Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis.

Anxiety Disorders / epidemiology Comorbidity Humans Mental Disorders / epidemiology Opioid-Related Disorders / epidemiology Prevalence Stress Disorders, Post-Traumatic / drug therapy
Anxiety disorders Mental disorders Meta-analysis Mood disorders Opioid use disorders Systematic review

Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 09 2022
Historique:
received: 13 04 2022
revised: 12 06 2022
accepted: 26 06 2022
pubmed: 8 7 2022
medline: 9 9 2022
entrez: 7 7 2022
Statut: ppublish

Résumé

Opioid use disorder (OUD) and mental disorders are major public health issues and comorbidity is common. Among people with OUD, comorbid mental disorders are associated with poorer health outcomes. To our knowledge, this is the first systematic review and meta-analysis to estimate prevalence of specific mental disorders among people with OUD. We searched Embase, MEDLINE, and PsycInfo from 1990 to 2021 for observational studies of depression, anxiety, post-traumatic stress disorder (PTSD), bipolar, personality, and other pre-specified mental disorders among people with OUD. We pooled current and lifetime estimates of each disorder using random-effects meta-analyses with 95% Confidence Intervals (CIs). Meta-regressions and stratified analyses were used to assess heterogeneity of prevalence estimates by methodological factors and sample characteristics. Of the 36,971 publications identified, we included data from 345 studies and 104,135 people with OUD in at least one pooled estimate. Among people with OUD, the prevalence of current depression was 36.1% (95%CI 32.4-39.7%), anxiety was 29.1% (95%CI 24.0-33.3%), attention-deficit/hyperactivity disorder was 20.9% (95%CI 15.7-26.2%), PTSD was 18.1% (95%CI 15.4-20.9%), and bipolar disorder was 8.7% (95%CI 6.7-10.7%). Lifetime prevalence of anti-social personality disorder was 33.6% (95%CI 29.1-38.0%) and borderline personality disorder was 18.2% (95% CI 13.4-23.1%). Sample characteristics and methodological factors, including sex, were associated with variance of multiple prevalence estimates. Our findings emphasise the need for access to mental disorder treatment among people with OUD. Specific mental disorder estimates may inform clinical guidelines, treatment services, and future research for people with OUD, including subpopulations with distinct treatment needs.

Sections du résumé

BACKGROUND
Opioid use disorder (OUD) and mental disorders are major public health issues and comorbidity is common. Among people with OUD, comorbid mental disorders are associated with poorer health outcomes. To our knowledge, this is the first systematic review and meta-analysis to estimate prevalence of specific mental disorders among people with OUD.
METHODS
We searched Embase, MEDLINE, and PsycInfo from 1990 to 2021 for observational studies of depression, anxiety, post-traumatic stress disorder (PTSD), bipolar, personality, and other pre-specified mental disorders among people with OUD. We pooled current and lifetime estimates of each disorder using random-effects meta-analyses with 95% Confidence Intervals (CIs). Meta-regressions and stratified analyses were used to assess heterogeneity of prevalence estimates by methodological factors and sample characteristics.
FINDINGS
Of the 36,971 publications identified, we included data from 345 studies and 104,135 people with OUD in at least one pooled estimate. Among people with OUD, the prevalence of current depression was 36.1% (95%CI 32.4-39.7%), anxiety was 29.1% (95%CI 24.0-33.3%), attention-deficit/hyperactivity disorder was 20.9% (95%CI 15.7-26.2%), PTSD was 18.1% (95%CI 15.4-20.9%), and bipolar disorder was 8.7% (95%CI 6.7-10.7%). Lifetime prevalence of anti-social personality disorder was 33.6% (95%CI 29.1-38.0%) and borderline personality disorder was 18.2% (95% CI 13.4-23.1%). Sample characteristics and methodological factors, including sex, were associated with variance of multiple prevalence estimates.
INTERPRETATION
Our findings emphasise the need for access to mental disorder treatment among people with OUD. Specific mental disorder estimates may inform clinical guidelines, treatment services, and future research for people with OUD, including subpopulations with distinct treatment needs.

Identifiants

DOI: 10.1016/j.drugalcdep.2022.109551 PMID: 35797876
pubmed: 35797876
pii: S0376-8716(22)00288-5
doi: 10.1016/j.drugalcdep.2022.109551
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109551

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Thomas Santo (T)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: t.santo@unsw.edu.au.

Gabrielle Campbell (G)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia; School of Psychology, The University of the Queensland, Brisbane, QLD 4072, Australia; National Centre for Youth Substance Use Research, University of Queensland, Brisbane, QLD Australia.

Natasa Gisev (N)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.

Daniel Martino-Burke (D)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.

Jack Wilson (J)

Matilda Centre, The University of the Sydney, Sydney, NSW 2006, Australia.

Samantha Colledge-Frisby (S)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.

Brodie Clark (B)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.

Lucy Thi Tran (LT)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.

Louisa Degenhardt (L)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles anxieux › Prevalence of mental disorders among people...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Comorbidité › Prevalence of mental disorders among people...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prevalence of mental disorders among people...
questionsmedicales.fr › Troubles mentaux › Prevalence of mental disorders among people...
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Troubles liés à l'usage de substances psychotropes › Troubles liés aux opiacés › Prevalence of mental disorders among people...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Prevalence of mental disorders among people...
questionsmedicales.fr › Troubles mentaux › Troubles liés aux traumatismes et au stress › Troubles de stress traumatique › Troubles de stress post-traumatique › Prevalence of mental disorders among people...